The Globe and Mail reports in its Friday edition that Echelon analyst Andrew Semple continues to rate Trulieve Cannabis "buy." The Globe's David Leeder writes that Mr. Semple cut his share target to $18 from $22. Analysts on average target the shares at $24.31. Mr. Semple says in a note: "We maintain our prior view that Trulieve's organic growth may trail peers in 2023 as it closes some underperforming assets and lacks exposure to certain key states. However, the company retains a deep pipeline of longer-term growth opportunities. These include: 1) Florida (pop. 21.8M) adult-use legalization, by far the most exciting growth opportunity for Trulieve, 2) adult-use legalization in Maryland on July 1 (pop. 6.2M), and 3) exposure to emerging medical markets, such as Georgia (pop. 10.8M) and West Virginia (pop. 1.8M). We single out Maryland, Georgia, and Florida as states with clear and large upside potential. With 39M people across these three states, we believe there is a potential market opportunity of more than $10-billion over the long term if all three states were to legalize adult-use cannabis (compared to sales of $2.2B today). These long-term opportunities continue to underpin our bullish view on Trulieve."